Exforge® (amlodipine/valsartan combination) in hypertension: The evidence of its therapeutic impact

Core Evidence

Volumn 4, Issue , 2009, Pages 1-11

  Krzesinski, Jean Marie ^a   Cohen, Eric P ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Amlodipine; Angiotensin II receptor blocker; Arterial hypertension; Calcium channel blocker; Combination therapy; Treatment; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; CALCIUM CHANNEL; CYCLOSPORIN; ENALAPRIL; FELODIPINE; FELODIPINE PLUS RAMIPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGINA PECTORIS; ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; GLOMERULUS FILTRATION RATE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PROTECTION; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 79959368568     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Lawes C, Vander Hoorn S, Rodgers A; for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518.
2. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-19. (Pubitemid 38293521)
3. Pardell H, Tresserras R, Armario P, Hernánez del Rey. Pharmacoeconomic considerations in the management of hypertension. Drugs. 2000;59(Suppl 2):12-20.
4. Goetzel R, Long S, Ozminkowski R, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004,46:398-412. (Pubitemid 38469017)
5. Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension. 2008;51:1275-1281.
6. Erdine S. How well is hypertension controlled in Europe? ESH Newsletter. 2007;8:No. 3. Available at: http://www.eshonline.org/education/newsletter.php.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. (Pubitemid 37430158)
8. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension, task force of the European Society of Hypertension and the European Society of Cardiology. J Hypertension. 2007;25:1105-1187. (Pubitemid 46924065)
9. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16:569-575. (Pubitemid 35021364)
10. Yusuf F, Sleight P, Dagenais G, et al. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
11. Yusuf F, Sleight P, Anderson C, et al. the ONTARGET investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
12. Alderman M, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349:594-598. (Pubitemid 27101885)
13. Stafford RS, Monti V, Furberg CD, Ma J. Long term and short term changes in antihypertensive prescribing by office based physicians in the United States. Hypertension. 2006;48:213-218. (Pubitemid 44309814)
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)
15. K/DOQI (Kidney Disease Outcomes Quality Initiative) Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Measurement of blood pressure in adults. Am J Kidney Dis. 2004;43:S92-S106.
16. Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med. 2005;353:487-497.
17. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001;19:149-155. (Pubitemid 32099288)
18. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens. 2005;19:491-496. (Pubitemid 40767186)
19. Stergiou GS, Makris B, Papavasiliou M, Efstahiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23:883-889. (Pubitemid 40523289)
20. Berlowitz D, Ash A, Hickey E, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963. (Pubitemid 29024127)
21. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28:385-407.
22. LeLorier J. The value of lowering blood pressure. Can J Cardiol. 2006;22:63-64.
23. van Zwieten P. Beneficial combinations of two or more antihypertensive agents. ESH-Newsletter. 2003;4:No.18. Available at: http://www.eshonline.org/ education/newsletter.php.
24. de Champlain J, Karas M, Assouline L, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens. 2007;9:168-178.
25. Burges RA, Gardiner DG, Gwilt M, et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors. J Cardiovasc Pharmacol. 1987;9:110-119. (Pubitemid 17212761)
26. Padia S, Howell N, Siragy H, Carey R. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537-544. (Pubitemid 43843872)
27. Franco M, Sanchez-Lozada LG, Bautista R, Johnson RJ, Rodriguez-Iturbe B. Pathophysiology of salt-sensitive hypertension: a new scope of an old problem. Blood Purif. 2008;26:45-48.
28. EMEA (European Medicines Agency). 2007. Available at: www.emea. europa.eu/ humandocs/PDFs/EPAR/exforge.
29. Plosker G, Robinson D. Amlodipine/valsartan fixed-dose combination in hypertension. Drugs. 2008;68:373-381.
30. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
31. Karas M, Lacourcière Y, LeBlanc AR, et al. Effects of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens. 2005;23:1251-1260. (Pubitemid 40862730)
32. Nissen S, Tuzcu M, Libby R, et al. for CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure; the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2226.
33. CAFE Investigators. Differential impact of blood pressure lowering drugs on the central aortic pressure and clinical outcomes. Circulation. 2006;113:1213-1225.
34. Nathan S, Pepine CL, Bakris GL. Calcium antagonists - effects on cardiorenal risk in hypertensive patients. Hypertension. 2005;46:637-642. (Pubitemid 43186729)
35. Bakris GL, Roto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303-1309. (Pubitemid 351693145)
36. Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2004;17:638-639; author reply 639-640.
37. Agodoa L, Appel L, Bakris G and The African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA. 2001;285:2719-2728.
38. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
39. Ridker PM, Danielson E, Rifai N, Glynn RJ; for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein. Primary report of the Val-MARC trial. Hypertension. 2006;48:73-79.
40. Galle J, Schwedhelm E, Pinnetti S, Böger H, Wanner C; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008;23:3174-3183.
41. Wogen J, Kreillick Ca, Livornesse RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9:424-429.
42. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20:72-80. (Pubitemid 46219403)
43. Mason RP, Marche R Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163. (Pubitemid 37532314)
44. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70:2109-2115. (Pubitemid 44871373)
45. Hirooka Y, Kimura Y, Sagaro Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens. 2008;30:267-276. (Pubitemid 351556172)
46. Maeda T, Kata M, Tajima A, et al. Additive effect of valsartan on exercise tolerance in hypertensive patients treated with amlodipine. J Hypertens. 2006;24(Suppl 6):399. Abstract PO4-154.
47. Allemann Y, Fraile B, Lambert M, Barbier M, Ferber R, Izzo J. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after single therapy (EX-FAST) study. J Clin Hyperten (Greenwich). 2008;10:185-194.
48. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adults patients with stage 2 hypertension. Clin Ther. 2007;29:279-289. (Pubitemid 46661857)
49. Fogari R, Zoppi A, Mugelini A, et al. Comparative evaluation of effect of valsartan/amlodipine and valsartan and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2008;51:217-222. (Pubitemid 351450598)
50. Fogari R, Derosa G, Zoppi A, et al. Effects of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007a;20:417-422. (Pubitemid 46441757)
51. Philipp T, Smith T, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580. (Pubitemid 47028551)
52. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9:335-364.
53. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. Journal of the American Society of Hypertension. 2008;2:294-302.
54. Trenkwalder R Schaetz R, Borbas E, et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 - The EXPRESS-C trial. J Hypertens. 2007:P24.261. Abstract S225.
55. Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther. 2008;25:399-411.
56. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007b;20:220-224.
57. Jönsson B, Hansson L, Stålhammar N-O. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med. 2003;253:472-480. (Pubitemid 36418933)
58. Dalhöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
59. Dahlöf B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. (Pubitemid 41265663)
60. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Valsartan in Acute Myocardial Infarction (VALIANT) Trial Investigators. N Engl J Med. 2003;349:1893-1906. (Pubitemid 37409706)
61. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure; Valsartan Heart Failure Trial (Val-HeFT) Investigators. N Engl J Med. 2001;345:1667-1675.
62. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmaco Economics. 2001;19:337-347.